Healthcare Industry News: HSMN NewsFeed
News Release - December 15, 2022
CardiaCare Announces Licensing and Distribution Agreement to Commercialize its Digital Neuromodulation Wearable for Non-invasive Atrial Fibrillation TreatmentREHOVOT, Israel, Dec. 15, 2022 -- (Healthcare Sales & Marketing Network) -- CardiaCare, a clinical stage digital therapeutic company developing the world's first non-invasive, personalized neuromodulation wearable for atrial fibrillation treatment, announced today the execution of a strategic licensing agreement with Dr. Reddy's Laboratories, a leading multinational pharmaceutical company based in India.
Atrial fibrillation (AF) is the most common sustained cardiac arrythmia, affecting tens of millions of patients worldwide. AF contributes to increased morbidity and mortality, mainly due to a 5-fold increased risk for stroke. Current standard of care includes pharmacological therapy or ablation, both of which have limited efficacy and various side effects, negatively impacting patients' quality of life.
The CardiaCare wearable device adopts a closed loop approach, integrating therapy and monitoring. It utilizes proprietary AI based ECG analysis algorithms to allow optimized and personalized atrial fibrillation treatment. Initial clinical data suggests that this novel therapeutic approach has both acute and cumulative effects, decreasing atrial fibrillation precursors and overall disease burden.
Ofer Halbreich, CardiaCare's CEO, commented: "Partnering with Dr. Reddy's Laboratories accelerates CardiaCare's evidence generation and commercialization activity, externally validating the potential of our game-changing technology for the treatment of atrial fibrillation. Our device enables safe, drug-free, at-home treatment, that has been shown to increase AF treatment efficacy and decrease costs. Our closed loop approach integrating therapy and monitoring optimizes and personalizes care, providing clinicians and patients better AF management."
Amos Ziv, CardiaCare's founder and CSO added: "We look forward to working closely with the Dr. Reddy's Laboratories team to help improve patient outcomes worldwide. We will continue to execute on our clinical development plans in other regions for this initial as well as additional indications in our pipeline."
CardiaCare is a clinical stage digital therapeutic company developing the world's first closed loop wearable for non-invasive, AI based treatment for cardiovascular care. For more information, visit the website and follow us on LinkedIn.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.